CION Kukatpally
Outcomes in ovarian cancer depend overwhelmingly on two things: the quality of the initial surgery, and access to PARP inhibitor maintenance therapy, which has transformed long-term survival for women with BRCA-mutated and platinum-sensitive disease. CION delivers the full spectrum — from primary or interval debulking to fertility-preserving approaches, first-line carboplatin-based chemotherapy to maintenance therapy — across 7 locations, backed by NABH accreditation and NCCN protocol-driven tumour board planning.
Ovarian cancer is the leading cause of gynaecological cancer death globally — not because it is the most common, but because it is so frequently diagnosed at an advanced stage. The ovaries lie deep in the pelvis, symptoms are vague and easily attributed to other conditions, and there is currently no effective population-wide screening test. Approximately 70% of women with ovarian cancer are diagnosed at Stage III or Stage IV, when the cancer has spread beyond the ovaries to the peritoneal cavity and distant organs.
In India, the median age at ovarian cancer diagnosis is under 55 — younger than in Western populations — meaning fertility preservation and hereditary risk assessment are especially relevant for Indian patients. According to the National Cancer Registry Programme (ICMR), ovarian cancer ranks among the top ten cancers in women across multiple Indian cities, with incidence rates rising in urban centres including Hyderabad.
The most important factors in ovarian cancer outcomes are: the completeness of surgical debulking (how much tumour is removed at the first operation), the quality of chemotherapy delivery, and access to maintenance therapy that delays recurrence. All three are central to CION's ovarian cancer protocol.
Ovarian cancer is not one disease. At CION, our tumour board evaluates every patient's histology and molecular profile so treatment is matched to the precise subtype.
Accounts for approximately 90% of all ovarian cancers. Develops from the cells covering the outer surface of the ovary or the fallopian tube lining. Subtypes have distinct behaviour and treatment implications:
Arise from the egg-producing cells of the ovary. Occur predominantly in young women and adolescents. The most common malignant type is dysgerminoma, followed by immature teratoma and yolk sac tumour. Highly chemosensitive — the majority are curable even at advanced stage. Fertility-preserving surgery is the standard of care for most germ cell tumours, followed by BEP chemotherapy (bleomycin, etoposide, cisplatin) where indicated.
Arise from the hormone-producing stromal cells of the ovary. Granulosa cell tumours are the most common type, often producing oestrogen and presenting with abnormal uterine bleeding. Generally slow-growing with a good prognosis at early stage. Treatment is surgical, with hormonal therapy or chemotherapy for advanced or recurrent disease. Inhibin B is a useful tumour marker for monitoring.
Ovarian cancer is frequently called a 'silent disease' — not because it produces no symptoms, but because its symptoms are vague, intermittent, and easily attributed to digestive or urinary conditions. The key is persistence: symptoms that occur more than 12 times per month and are new or more severe than usual warrant specialist evaluation.
If you have experienced any of these symptoms persistently — especially if you have a family history of ovarian or breast cancer or a known BRCA mutation — consult a gynaecologic oncologist at your nearest CION location without delay.
Protective factors include oral contraceptive use (reduces risk by up to 50% with long-term use), multiple pregnancies, and breastfeeding.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Kukatpally
CION Kompally
CION Ameerpet
CION Tolichowki
CION Masab Tank
CION L.B. Nagar
CION Banjara Hills
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you've just been diagnosed or want to understand your PARP inhibitor options — talk to a CION specialist today.
Ovarian cancer cannot be definitively diagnosed without surgical tissue — but imaging and tumour markers guide the decision to operate and help plan the surgical approach. CION's diagnostic pathway is thorough and efficient.
NCCN guidelines now recommend germline BRCA1/BRCA2 testing for every woman diagnosed with ovarian cancer — not only those with a family history. This is because:
CION's genetic counselling service offers BRCA testing with pre- and post-test counselling for patients and their families. Somatic tumour testing for homologous recombination deficiency (HRD) is also available to identify additional patients who may benefit from PARP inhibitors beyond BRCA-mutated cases.
Ovarian cancer is staged using the FIGO (International Federation of Gynecology and Obstetrics) system. Stage at diagnosis is the single strongest predictor of outcome.
| Stage | FIGO | Extent of Disease | 5-Year Survival | Primary Treatment |
|---|---|---|---|---|
| Stage I | IA–IC | Confined to one or both ovaries | 85–95% | Surgery ± chemotherapy |
| Stage II | IIA–IIC | Spread to pelvic organs (uterus, fallopian tubes) | 70–80% | Surgery + adjuvant chemotherapy |
| Stage III | IIIA–IIIC | Peritoneal spread or retroperitoneal lymph nodes | 40–60% | Debulking surgery + chemotherapy ± PARP inhibitor maintenance |
| Stage IV | IVA–IVB | Distant spread (pleural fluid, liver parenchyma, lung, groin nodes) | 15–30% | NACT → interval debulking, or systemic therapy + maintenance |
5-year survival estimates are for epithelial ovarian cancer based on international data. Individual outcomes depend on tumour grade, histological subtype, BRCA status, and completeness of surgical debulking.
Specialist tumour-board-led care, NCCN protocols, and access to PARP inhibitor maintenance translate into measurable survival differences.
*1-year survival. Source: CION internal outcomes data vs ICMR National Cancer Registry Programme (NCRP).
CION follows NCCN and ESMO protocol-driven treatment for all ovarian cancer subtypes and stages. Every case is reviewed by a multidisciplinary tumour board before treatment begins.
Surgery is the cornerstone of ovarian cancer management. The primary surgical goal is optimal cytoreduction — removal of all visible tumour, or at minimum reduction of residual disease to nodules under 1cm. The extent of residual disease after debulking is the single strongest predictor of survival; every millimetre matters.
Radiation therapy has a limited but important role in ovarian cancer management. CION's radiation oncology team — led by Dr. Venkata Sushma P — uses advanced techniques in specific situations:
Not every patient with advanced ovarian cancer can or should undergo primary debulking surgery upfront. For patients with extensive Stage IIIC or Stage IV disease where complete cytoreduction is not achievable at diagnosis — due to performance status, medical comorbidities, or tumour distribution — neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is the NCCN-recommended alternative pathway.
This approach is the standard of care for a significant proportion of advanced ovarian cancer patients, yet few hospital treatment pages in Hyderabad describe it. CION's NACT + IDS pathway:
If you have been told your ovarian cancer is 'too advanced for surgery' without being offered NACT first — or if you have not been assessed by a gynaecologic oncology surgical team — request a second opinion from CION before accepting a non-surgical pathway.
PARP inhibitors are one of the most impactful advances in ovarian cancer treatment of the past decade. If you have been diagnosed with ovarian cancer — particularly BRCA-mutated or platinum-sensitive disease — understanding PARP inhibitors is essential to your treatment planning.
PARP (Poly ADP-Ribose Polymerase) is a DNA repair enzyme. Cancer cells with BRCA mutations are already deficient in one DNA repair pathway; PARP inhibitors block a second pathway, causing cancer cell death through a mechanism called synthetic lethality. Critically, healthy cells with functioning BRCA genes can use alternative repair pathways — so PARP inhibitors are selectively toxic to BRCA-mutated cancer cells while largely sparing normal tissue.
PARP inhibitors (olaparib, niraparib) are oral tablets taken daily — no infusion, no hospital admission. They are typically continued for 2 years or until disease progression. Side effects include fatigue, nausea, and anaemia, all of which are manageable with monitoring and dose adjustment. CION's medical oncology team — led by Dr. N. Kiranmayee — performs regular blood count monitoring throughout PARP inhibitor maintenance.
Ovarian cancer recurs in approximately 70–80% of patients with advanced-stage disease, even after apparently successful primary treatment. Recurrence is not a treatment failure — it is a transition to a new phase of management that requires different clinical decisions. The most important distinction is the platinum-free interval (PFI) — the time between completing platinum chemotherapy and relapse:
CION's medical oncology team reviews every case of recurrence through the tumour board to determine the platinum-free interval, assess re-treatment options, and discuss clinical trial eligibility where appropriate.
Treatment costs vary based on stage, surgical extent, and whether systemic therapy is required. The following ranges reflect current Hyderabad market data:
| Treatment | Approx. Cost (INR) | Notes |
|---|---|---|
| Debulking Surgery (Cytoreductive) | ₹3,00,000 – ₹9,00,000 | Varies by extent; multivisceral resections at higher end |
| Staging Surgery (Early-Stage) | ₹1,50,000 – ₹3,50,000 | TH + BSO + lymph node sampling |
| Fertility-Preserving Surgery | ₹1,20,000 – ₹2,50,000 | Unilateral SO; staging biopsies additional |
| Chemotherapy — Carboplatin + Paclitaxel (per cycle) | ₹25,000 – ₹80,000 | 6 cycles standard; IP chemo at higher end |
| Bevacizumab Maintenance (per cycle) | ₹60,000 – ₹1,50,000 | Continued up to 15 months; insurance varies |
| PARP Inhibitor Maintenance (per month) | ₹50,000 – ₹1,20,000 | Olaparib / niraparib oral; may be covered under insurance |
| Full Multi-modal Treatment | ₹3,00,000 – ₹12,00,000+ | Depending on stage, sequence, and duration |
Costs are indicative. A personalised treatment cost estimate is provided after your initial oncology consultation at CION.
Eighteen reasons our patients pick CION — structured NACT pathway, PARP maintenance, fertility-preserving surgery, and HIPEC.
1,000+ Ovarian cancer cases
7 locations across Hyderabad
5-Star NABH Accredited
NCCN & ESMO Protocol Adherence
NACT + Interval Debulking pathway
PARP inhibitor maintenance therapy
Germline BRCA testing at diagnosis
Fertility-preserving surgery
HIPEC coordinated
Intraperitoneal chemotherapy
Bevacizumab maintenance
Recurrent disease pathway
Full integrative support
Multidisciplinary tumour board review
Dedicated Second Opinion service
EMI facility
4.8 / 5 Google rating
35+ centres across Telangana & AP
Ovarian cancer management requires close coordination between surgical oncology, medical oncology, radiation oncology, genetic counselling, and pathology. At CION, every ovarian cancer case is reviewed by a multidisciplinary tumour board before treatment:
CION operates 35+ centres across Telangana and Andhra Pradesh. Find your nearest gynae-oncology specialist or explore care options in your city.
Travelling for treatment? We may have a centre right where you are — across Telangana and Andhra Pradesh.
Not seeing your city? Call us — we'll connect you to the nearest CION centre or arrange a teleconsultation.
If you've been told your cancer is "too advanced for surgery" without NACT being offered first — a second opinion may open a pathway that was not previously available.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Common questions about ovarian cancer treatment in Hyderabad — answered by CION's gynae-oncology team.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.